Johnson & Johnson’s Reports the CE Mark Approval for Dual Energy Thermocool Smarttouch SF Catheter for Cardiac Arrhythmias
Shots:
- The CE mark of Thermocool Smarttouch SF Catheter for cardiac arrhythmias was based on SmartfIRE trial in European patients with refractory PAF that depicted 100% acute success rate & first-pass isolation achievement in 96.8% of veins (published in Apr 2024). The Trupulse Generator hardware compatibility is anticipated in H1’25
- The company has concluded recruitment in SmartPulse (n=250; 27 sites in the US) & PulseSmart (n=136; 7 sites in Australia & Canada) studies assessing the device in patients with PAF for global availability
- The platform consists of an irrigated, contact-force sensing Thermocool Smarttouch SF Catheter & Trupulse Generator that enables electrophysiologists to toggle b/w the radiofrequency & pulsed field energies on the generator monitor
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related Posts:- Johnson & Johnson Reports Nipocalimab’s BLA Submission to the US FDA for Treating Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
